# Finasteride *Also known as: Propecia, Proscar* For lifters worried about thinning hair, finasteride comes up as a way to preserve hair while using TRT or other androgens. The hoped-for benefit is less DHT-related hair loss without giving up training progress. Hair benefits take months; sexual function and mood are important parts of the trade-off. Educational information only — not medical advice. Modelled values are not individual measurements or dosing recommendations. ## Dosage & duration Oral finasteride · separate US label indications ### Male pattern hair loss **Product label** - **Dose:** 1 mg - **How often:** Once daily; with or without food - **How long:** Ongoing treatment; reassess benefit over months This is the Propecia indication. A 5 mg tablet is not a five-times-better hair-loss treatment. - [Organon — Propecia US prescribing information](https://www.organon.com/product/usa/pi_circulars/p/propecia/propecia_pi.pdf) — Sections 2, 6, 12.3:1 mg daily for male pattern hair loss; benefit generally takes at least 3 months. Table 4: healthy men 19–42, n 12; repeated 1 mg/day Cmax 9.2 ng/mL, AUC 0–24=53 ng·h/mL, Tmax 1.3 h; half 4.5 h is explicitly FIRST-dose while other values are last-dose. Accessed 2026-10-09. - [Roberts et al.1999 — finasteride dose-ranging hair-loss trials](https://pubmed.ncbi.nlm.nih.gov/10495375/) — Original randomized dose-ranging studies in men 18–36:1 mg and 5 mg had similar efficacy; 1 mg selected for further development. Indexed abstract verified 2026-10-09. ### Enlarged prostate (BPH) **Product label** - **Dose:** 5 mg - **How often:** Once daily - **How long:** Ongoing treatment with clinical follow-up The Proscar indication is symptomatic BPH with an enlarged prostate. - [Organon — Proscar US prescribing information](https://www.organon.com/product/usa/pi_circulars/p/proscar/proscar_pi.pdf) — Sections 1–2:5 mg daily for symptomatic benign prostatic hyperplasia in men with enlarged prostate; this is a different indication from hair-loss treatment. Accessed 2026-10-09. These are indication-specific label doses. The plot does not determine the appropriate treatment or dose. Dose-context sources checked: 2026-10-09. ## At a glance - **Why lifters discuss it:** Keep hair while training - **Gains question:** DHT reduction ≠ lost gains Sources or review notes: [5](https://pubmed.ncbi.nlm.nih.gov/24326421/). - **Hair timeline:** Judge it over months Sources or review notes: [1](https://www.organon.com/product/usa/pi_circulars/p/propecia/propecia_pi.pdf), [2](https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products). **Catalog evidence label (not clinical review):** Human RCT evidence ## The hair-versus-gains question - **Hair takes time:** Finasteride treats male-pattern hair loss; benefit generally takes at least three months. - **What about strength?:** An older-men testosterone trial found no loss of measured strength or lean-mass benefits with finasteride. - **How you feel matters:** New sexual-function or mood changes deserve medical attention. These findings do not establish that every androgen or PED combination is hair-safe. Visual sources checked: 2026-10-09. - [Organon — Propecia US prescribing information](https://www.organon.com/product/usa/pi_circulars/p/propecia/propecia_pi.pdf) — Sections 2, 6, 12.3:1 mg daily for male pattern hair loss; benefit generally takes at least 3 months. Table 4: healthy men 19–42, n 12; repeated 1 mg/day Cmax 9.2 ng/mL, AUC 0–24=53 ng·h/mL, Tmax 1.3 h; half 4.5 h is explicitly FIRST-dose while other values are last-dose. Accessed 2026-10-09. - [EMA — finasteride safety review, 2025](https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products) — EU review confirmed suicidal thoughts as a finasteride-tablet side effect with unknown frequency; sexual-function problems and mood changes need medical attention. Accessed 2026-10-09. - [Borst et al.2014 — testosterone with finasteride randomized trial](https://pubmed.ncbi.nlm.nih.gov/24326421/) — Original indexed abstract read 2026-10-09:60 men≥60 years with low testosterone,52-week factorial study. Finasteride did not alter measured testosterone-related strength/fat-free-mass improvements. This is not a hair-protection trial or proof about every PED stack. PMC full-text route challenged access; no full-text claim made. ## Overview ## Why it appears in TRT and bodybuilding discussions The practical aim is to keep a receding hairline or thinning crown from becoming the price of using androgens. Some lifters also ask whether lowering DHT will cost them strength or lean mass. Those are separate questions: a hair-loss treatment is not automatically an anti-muscle treatment. ## Will finasteride hurt muscle gains? A randomized study in men aged 60 and older found that adding finasteride did not alter the measured muscle-strength and fat-free-mass improvements from testosterone. That is useful evidence against the blanket claim that lowering DHT necessarily cancels testosterone’s muscle effects. It does not prove identical results for younger lifters or multi-drug steroid use. ## Does it protect hair from every steroid? That distinction is easy to miss. Finasteride reduces testosterone’s conversion to DHT; it is not a clinical guarantee of protection from every androgen someone might add. Claims that a particular stack is “hair-safe” go beyond the evidence reviewed here. ## What do the 1 mg and 5 mg labels mean? The hair-loss dose and the prostate dose answer different treatment needs. Dose-ranging hair-loss trials found similar efficacy with 1 mg and 5 mg, so the larger prostate dose is not a shortcut to faster regrowth. The visible dose guide keeps the two indications separate. ## What is the real trade-off? The aim is better hair without an unacceptable effect on sexual function or mood. Discuss new symptoms rather than trying to read them from DHT theories or a plot. The EMA advises people taking 1 mg for hair loss to stop and seek medical advice if mood changes occur. Tell the clinician interpreting PSA that finasteride is being used, and keep crushed/broken tablets away from anyone who is or may be pregnant. The relative curve shows oral drug timing. It does not predict hair density, DHT suppression or the effect of a topical product. ## Relative timing model Relative oral timing estimate **Output:** Finasteride: relative timing (relative units). Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength. Illustrates oral drug timing, not DHT suppression or hair growth. ### Timing assumptions and scale The Propecia label gives a 4.5 h first-dose half-life and a 1.3 h last-dose peak time in healthy men. This simplified curve combines those timings as an explicit approximation; it is not a calibrated plasma model. One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales. - **Timing half-life used:** 4.5 hours - **Absorption half-life assumed:** 0.3151872 hours - **Reference amount for the relative scale:** 1 mg - Absorption half-life 0.315187 h is mathematically reconstructed to place the peak at 1.3 h; it was not directly measured. - One 1 mg input has a peak of 1 relative unit, independent of the example dose. Linear scaling and repeated-dose addition are illustrative. - The source peak 9.2 ng/mL and AUC 53 ng·h/mL are steady-state observations, not single-dose calibration. - Saturable enzyme binding and low-dose nonlinearity are omitted; the curve cannot estimate DHT, treatment benefit or a personal stopping interval. ### Model sources - [Organon — Propecia US prescribing information](https://www.organon.com/product/usa/pi_circulars/p/propecia/propecia_pi.pdf) — Sections 2, 6, 12.3:1 mg daily for male pattern hair loss; benefit generally takes at least 3 months. Table 4: healthy men 19–42, n 12; repeated 1 mg/day Cmax 9.2 ng/mL, AUC 0–24=53 ng·h/mL, Tmax 1.3 h; half 4.5 h is explicitly FIRST-dose while other values are last-dose. Accessed 2026-10-09. - [Suzuki et al.2010 — nonlinear finasteride PK/PD model](https://www.jstage.jst.go.jp/article/dmpk/25/2/25_2_208/_pdf/-char/en) — Full text: saturable enzyme binding and dose/history-dependent PK, especially 0.2 mg. Table 1 single 1 mg n 11 Cmax 9.89 ng/mL, AUC 0–24=49.29, half 4.15 h. The published nonlinear binding model is not the linear timing explorer used here. Accessed 2026-10-09. **Revision:** finasteride-oral-relative-timing-2026-10 · version 1 ## Harm reduction - **Interaction notes:** Tell the clinician interpreting PSA that finasteride is being used. Sexual-function and mood changes need review. ## Sources and review notes Summary source check: 2026-10-09; see source notes 1, 2. This does not certify medical review of the whole page. ### Notes on the quick facts - **Why lifters discuss it:** Hair preservation alongside TRT/PED use is the goal in the discussions reviewed. Source check: 2026-10-09; not a medical review. - **Gains question:** An older-men testosterone trial found no loss of the measured strength and lean-mass benefits with finasteride. Source check: 2026-10-09; not a medical review. - **Hair timeline:** The hair-loss label generally needs at least 3 months before benefit; sexual or mood changes deserve earlier review. Source check: 2026-10-09; not a medical review. ### References 1. [Organon — Propecia US prescribing information](https://www.organon.com/product/usa/pi_circulars/p/propecia/propecia_pi.pdf) — Sections 2, 6, 12.3:1 mg daily for male pattern hair loss; benefit generally takes at least 3 months. Table 4: healthy men 19–42, n 12; repeated 1 mg/day Cmax 9.2 ng/mL, AUC 0–24=53 ng·h/mL, Tmax 1.3 h; half 4.5 h is explicitly FIRST-dose while other values are last-dose. Accessed 2026-10-09. 2. [EMA — finasteride safety review, 2025](https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products) — EU review confirmed suicidal thoughts as a finasteride-tablet side effect with unknown frequency; sexual-function problems and mood changes need medical attention. Accessed 2026-10-09. 3. [Roberts et al.1999 — finasteride dose-ranging hair-loss trials](https://pubmed.ncbi.nlm.nih.gov/10495375/) — Original randomized dose-ranging studies in men 18–36:1 mg and 5 mg had similar efficacy; 1 mg selected for further development. Indexed abstract verified 2026-10-09. 4. [Organon — Proscar US prescribing information](https://www.organon.com/product/usa/pi_circulars/p/proscar/proscar_pi.pdf) — Sections 1–2:5 mg daily for symptomatic benign prostatic hyperplasia in men with enlarged prostate; this is a different indication from hair-loss treatment. Accessed 2026-10-09. 5. [Borst et al.2014 — testosterone with finasteride randomized trial](https://pubmed.ncbi.nlm.nih.gov/24326421/) — Original indexed abstract read 2026-10-09:60 men≥60 years with low testosterone,52-week factorial study. Finasteride did not alter measured testosterone-related strength/fat-free-mass improvements. This is not a hair-protection trial or proof about every PED stack. PMC full-text route challenged access; no full-text claim made. 6. [Suzuki et al.2010 — nonlinear finasteride PK/PD model](https://www.jstage.jst.go.jp/article/dmpk/25/2/25_2_208/_pdf/-char/en) — Full text: saturable enzyme binding and dose/history-dependent PK, especially 0.2 mg. Table 1 single 1 mg n 11 Cmax 9.89 ng/mL, AUC 0–24=49.29, half 4.15 h. The published nonlinear binding model is not the linear timing explorer used here. Accessed 2026-10-09. --- **Canonical URL:** https://anabolicplotter.com/compounds/finasteride/ **Methodology:** https://anabolicplotter.com/methodology/ **Plot:** https://anabolicplotter.com/plot?compound=finasteride